ASDA Partners With Avery Berkel and Hanshow to Enhance UK Sustainability and Supermarket Shopping Experience
25.7.2023 11:00:00 EEST | Business Wire | Press release
ASDA, in partnership with Avery Berkel and Hanshow, has launched a strategic project to create the first sustainability trial store in the UK that utilizes leading ESL technology and digital retail solutions to enhance operations and improve the shopping experience for customers. This partnership aims to promote refillable solutions for supermarket shopping in the UK, with a focus on sustainability and customer experience. Avery Berkel and Hanshow collaborated to leverage their expertise in retail scales, enterprise scale management, and electronic shelf labels (ESLs) to develop a sustainable solution for the Middleton store, eliminating the need for physical labels and creating a zero-waste solution for ASDA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713235215/en/
Avery Berkel and Hanshow's solutions installed in ASDA (Photo: Business Wire)
The solutions offered by Avery Berkel and Hanshow allow ASDA to carry out its commitment to zero-waste shopping through its bring-your-own-container solution and promoting its ‘Refill Price Promise’ program, which guarantees lower prices to help customers shop more sustainably. ESL technology reduces the cost and time of manual updates, while allowing ASDA to make real-time changes to prices and promotions. It also allows customers to see price differences in wrapped and unwrapped versions of the same product. The solutions make it easier for customers to shop sustainably and are part of a greater effort to make ASDA’s refill areas more efficient and green.
Avery Berkel and Hanshow’s ESL technology streamlines in-store change administration and management, ensuring real-time price and product updates to keep shelves up to date and compliant with regulations. This flexibility to adjust prices and promotions enables retailers to respond promptly to market trends and customer demands, while reducing costs associated with label stock holding and consumables. Increased productivity and efficiency allow employees to focus on providing better customer service.
Customizability is another key feature of the ESL technology innovations, enabling ASDA and other retailers to incorporate custom fonts, images, logos, and graphics into the labels. This allows for brand alignment and a consistent visual identity across stores. The on-screen barcodes and QR codes facilitate easy scanning, streamlining checkout processes and enhancing operational efficiency.
The components of Avery Berkel and Hanshow’s solution are seamlessly integrated to provide shoppers with an enriching refill experience while emphasizing sustainability. Unlike standard printed shelf and product labels, the total refill solution offers additional product information such as refill instructions, ingredients, allergens, and storage details, encouraging sustainability in ASDA stores.
Avery Berkel and Hanshow aimed to revolutionize the shopping experience by making sustainable choices more accessible and engaging for customers. The shopper interface, designed to be simple and intuitive, ensures that even customers unfamiliar with this technology can easily navigate and participate. The collaboration among ASDA, Avery Berkel and Hanshow has led to a total solution that not only benefits the retail industry and its customers, but also provides a green solution and encourages more environmentally friendly retail practices and shopping habits. Consumer demand for sustainable retail will continue to grow in the future. Hanshow will strive to provide the sustainable retail solutions by continuously innovating and improving their digital labelling technology to meet the changing needs of customers and reduce environmental impact.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230713235215/en/
Contact information
Zishan Cai
zishan.cai@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom